The same week that drug manufacturer Merck pulled its highly profitable painkiller, Vioxx, from the market last September, acknowledging that it was linked to heart attacks and strokes, a Las Vegas legend dropped into our local poker game. Ray is one of poker’s few long-term success stories. A math wiz, highly praised author of several authoritative books on game theory and high-limit poker, and a practicing Buddhist, Ray was reminiscing about his early days in Las Vegas.
“Cheating was rampant,” he said. “Stripped decks, wired hands, coolers, seconds, holdouts and marked cards. You name it, they did it — the dealers and the players.”
Ray had been able to make a great living in poker because he assumed the games might be rigged and acted accordingly. He studied the players and dealers, even watched videos of how card dealers dealt off the bottom of the deck or from the middle. He always expected the worst and was prepared.
“You weren’t bothered playing with a bunch of crooks?” I asked.
Ray laughed. “You got to play with someone. We all have cheat in us, given the right circumstances.” He smiled slyly. “But even cheats don’t cheat all the time. The trick is to know when and how.”
With its spectacular medical advances, Big Pharma is the only game in town. We cannot walk away; we must play. But unlike Ray, we are reluctant to assume that drug companies are rigging the outcome. Without this requisite skepticism, we are at their mercy — in this case, with fatal consequences. The U.S. Food and Drug Administration has linked Vioxx, since it was released in 1999, to more than 27,000 acute heart attacks and sudden cardiac deaths. What the agency didn’t report was its own culpability in the debacle.
Even the disclosure of tragic deaths, though, won’t stop the same malfeasance from happening again. In order to protect ourselves as patients, we need to know how the game might be fixed. Dissecting the way that Merck developed Vioxx gives us a perfect opportunity.
I was initially reluctant to write another piece on the Vioxx scandal. The mainstream press has more than adequately pointed the finger of blame at Merck for knowing the cardiovascular risks of Vioxx and yet minimizing them to reap huge economic rewards. The medical literature has been equally damning. Two months after Vioxx was recalled, Dr. Richard Horton, editor in chief of the British medical journal Lancet, wrote: “With Vioxx, Merck and the F.D.A. acted out of ruthless, short-sighted, and irresponsible self-interest.”
But the medical literature related to Vioxx suggests an even more onerous possibility, which is that Merck intentionally designed its studies to avoid discovering the truth about the potential C.V. risks of Vioxx. I have not been privy to the company’s private staff meetings and internal documents. But it has been my experience that undertaking any major research study involves extensive consultation between experts in all pertinent fields, including pharmacologists, epidemiologists, statisticians and business managers. Given the enormous intellectual investment in the design of a drug like Vioxx, it is reasonable to presume that all potential outcomes were seriously entertained. I must presume that Merck would factor in what might happen to Vioxx sales with each study result. And so it’s hard to escape the sadly cynical conclusion that the company consciously crafted its tests to avoid exposing the risks of Vioxx to the public.
After all, the stakes of new drug development are enormous. Only a fraction of new drugs submitted to the FDA for approval make it to market; the average cost per approved drug is over $800 million. Any drug that makes it into the marketplace is a potential bonanza to be coddled, cherished and protected. A drug patent lasts 17 years, and then the drug is thrown to the generic manufacturers. The FDA approved Vioxx for sale in May 1999. By 2004, 20 million Americans had taken the painkiller and its annual sales exceeded $2.5 billion. Is it any wonder that Merck sought to present Vioxx to the public in the best possible light?
To understand Merck’s approach, we need a crash course in biology. COX (cyclooxygenase) is an enzyme in the body that produces an inflammatory response — swelling, fever and pain. Drugs that reduce COX activity are called NSAIDs, and traditionally include aspirin and ibuprofen. But COX is present throughout the body and has a host of other effects, some of which are beneficial. For example, it helps protect the lining of the G.I. (gastrointestinal) tract from ulceration and bleeding.
Approximately 1 in 1,200 patients taking traditional NSAIDs for at least two months will die from G.I.-related complications. A conservative estimate: 16,500 NSAID-related deaths occur every year in the United States, approximately equivalent to the number of deaths from AIDS.
The holy grail of anti-inflammatories would be a COX inhibitor without this side effect. This became a real possibility in 1990, when COX was shown to exist as two chemically distinct enzymes — COX-1 and COX-2. COX-1 protects the G.I. tract, while COX-2 is responsible for the inflammatory response. The obvious answer to the G.I. complications: develop a drug that inhibits COX-2 but not COX-1.
Give Merck credit. It developed Vioxx, a drug with the same degree of anti-inflammatory and anti-pain response as NSAIDs, but with a significant reduction in G.I. complaints and complications.
But medicine rarely comes in such neat categories. As far back as 1984, Garret FitzGerald and his colleagues at the University of Pennsylvania, writing in the New England Journal of Medicine, showed that the COX enzyme might prevent arterial blood clot formation. FitzGerald suggested that this side effect might mean little in healthy persons but could be dangerous to patients with severe atherosclerosis. Which sounds reasonable — a high level of an anti-clotting enzyme wouldn’t be necessary in normal vessels, but would be necessary in damaged vessels in which clot formation was more likely.
In 1997, with Vioxx still in clinical trials, FitzGerald himself consulted with Merck. According to Merck’s position statement, recently filed in a U.S. District Court in Louisiana, in response to a class-action lawsuit, FitzGerald warned the company that COX-2 had a possible anti-clotting benefit. He expressed concern that suppression of this mechanism by a “coxib” drug such as Vioxx might increase the risk of blocked arteries.
Merck responded to FitzGerald’s research by re-analyzing all of its Vioxx clinical data, and included FitzGerald’s potentially worrisome lab data in its FDA application. (This data was published in 1999 in the Journal of Pharmacology and Experimental Therapeutics.) Merck also declared that it had adopted the standard procedure for “facilitating rigorous scientific analysis, on an ongoing basis, of all competing hypotheses about potential CV risks or benefits from Vioxx.”
Was this a sufficient evaluation of a potentially serious side effect of Vioxx? Or should more have been done? Given that it is standard practice to assess all serious potential risks of new drugs, FitzGerald’s concern should have been directly addressed.
But rather than design a study focused on the C.V. risks of Vioxx, Merck created the VIGOR (Vioxx Gastrointestinal Outcomes Research) study in 2000. It compared the incidence of G.I. complications of Vioxx to naproxen, another conventional NSAID, whose most popular brand is Aleve. The goal was to prove that Vioxx was an equally effective but safer drug than an over-the-counter NSAID. Unfortunately, the study, published in the New England Journal of Medicine, revealed a twofold increase in C.V. risk for patients who took Vioxx. Of course, Merck acted surprised. What Merck didn’t tell us is that it had stripped the deck of patients at high risk for heart disease.
In the VIGOR study, 80 percent of patients were women with an average age of 58, with Merck being well aware that women, on average, develop C.V. disease 10 years later than men. Only 4 percent of the total subjects had a prior history of C.V. disease and were felt to be at high risk for further C.V. events. It was no surprise, then, that 38 percent of the heart attacks in the group of patients who took Vioxx came from this small 4 percent subgroup.
Ironically, it was Merck’s failure to eliminate these few high-risk patients that allowed the C.V. effects of Vioxx to be detected. According to a review of coxibs in the New England Journal of Medicine, published in 2001, if these few high-risk patients had been excluded from the VIGOR study, the difference between Vioxx and naproxen would not have been significant. Therefore Vioxx may have never been taken off the market.
But there’s more.
Anyone who’s gambled in a casino knows that the key to winning is to get lucky initially and quit before the odds catch up with you. Get in and get out before the odds get a chance to declare themselves.
To understand the risks involved with a coxib, it is necessary to conceptualize risk as a function of time. The risk of electrocution is immediate. You don’t grab a hot wire and get electrocuted next year. It’s now or never. Similarly, a fatal allergic reaction to a penicillin injection happens within minutes, not in six months. In assessing risk factors with a predictable time of occurrence, it is easy to determine the study period. But other risks can take years or decades to manifest themselves.
It took many years to recognize the detrimental effects of hormone replacement therapy, or the time lag between sun exposure and the subsequent development of a malignant melanoma. Such correlations require following large groups of patients for extended periods of time. A major source of our understanding of cholesterol levels and the development of C.V. disease came from large-population longitudinal studies such as the Framingham Heart Study, which began in 1948 and is still ongoing.
It is self-evident that risk factors can be present for many years before becoming clinically observable. Although elevated levels of cholesterol increase the risk of a heart attack, the rate of heart attacks in teenagers with high cholesterol is far less than that of middle-aged adults with similar cholesterol levels. The cholesterol effect is cumulative; atherosclerosis takes time to become manifest.
If we wanted to minimize or negate the apparent effect of cholesterol on heart disease, we would study the youngest patients we could, and for the shortest period of time. If we ran a nine-month study to compare the incidence of heart attacks in a group of 10-year-olds with high cholesterol vs. normal controls, it is highly unlikely that we would see a difference.
The Framingham study has been ongoing for more than 50 years. Merck’s VIGOR study followed its patients for an average of nine months. Even this short period revealed a very disturbing trend.
During the first six weeks of the study, there was no significant difference between the two drugs. As the follow-up period continued, the patients taking naproxen clearly were having fewer heart attacks than those taking Vioxx. But between months 8 and 11, the naproxen rate was relatively constant, while the Vioxx rate appeared to be accelerating. It was at this critical point that Merck concluded its trial.
When asked why it concluded its VIGOR study at this key juncture, a Merck spokesperson replied with a terse e-mail: “VIGOR was an endpoint-driven study and it ended when it was designed to end.”
Merck repeatedly contended that it was actively investigating possible reasons for the adverse findings in the short VIGOR study. One of them was that the difference between Vioxx and naproxen could be best explained as a cardio-protective benefit of naproxen as opposed to an untoward side effect of Vioxx. Most researchers disagree. To date, no large-scale study has demonstrated more than a possibly small protective effect of naproxen, and certainly not of the magnitude that would explain the VIGOR difference. In fact, a recent study of naproxen and prevention of Alzheimer’s disease was halted because of an apparent increase in C.V. events.
Listen to Peter S. Kim, president of Merck Research Laboratories, explain why Vioxx had a higher C.V. complication rate than naproxen. “Because the VIGOR study compared two drugs — Vioxx and naproxen — and did not contain a placebo arm, it was not possible to conclude, based on this study alone, whether naproxen was having a beneficial CV effect or whether Vioxx was having a detrimental CV effect.”
When I asked Merck why it didn’t include a placebo group in the study, which would have underscored the C.V. effects of Vioxx, it referred me again to its court statement: “For ethical reasons, Merck could not conduct a placebo-controlled study in a population that required pain medicine (because patients in the placebo arm would receive no pain relief).”
Yet placebo control studies are commonly used to study anti-pain medications. Indeed, many peer-reviewed osteoarthritis and rheumatoid arthritis studies of NSAIDs and coxibs, including Vioxx, have included a placebo group for comparison. (Unfortunately, these studies were of too short a duration — 6-12 weeks — to assess any long-term C.V. effect. Merck, nevertheless, cites the data to show no evidence of C.V. effect of Vioxx.)
In an August 2001 article in the Journal of the American Medical Association, Drs. Mukherjee, Topol and Nissen from the Cleveland Clinic compared rates of heart attacks in trials performed with selective COX-2 inhibitors, including Vioxx, to heart attack rates compiled from a large number of studies on aspirin for heart disease prevention. Their review included 48,000 patients; the Merck VIGOR trial had 8,000.
The authors concluded: “The available data raise a cautionary flag about the risk of cardiovascular events with COX-2 inhibitors.” Even more compelling, they stated: “We believe that it is mandatory to conduct a trial specifically assessing cardiovascular risk and benefit of these agents. Until then, we urge caution in prescribing these agents to patients at risk for cardiovascular morbidity.”
Merck did make a motion in that direction. According to an article in the New York Times earlier this year, the company planned to initiate a major C.V. risk study called VALOR in 2002. But just days before company researchers were to submit the study’s protocol to the FDA, the project was abruptly halted. Merck did not explain why. It issued a general statement, saying that as it was designing the study, “we continued to ask ourselves and our consultants whether this was the right way to definitely answer” the question of whether Vioxx posed C.V. risks. “We ultimately decided not to conduct that particular study.”
In 2002, with Vioxx selling extremely well, Merck was no doubt convinced that the odds of keeping the painkiller on the market remained in its favor. After all, when the VIGOR study revealed that patients who took Vioxx showed a twofold increase in heart attacks, Merck must have figured that it could face potential lawsuits. Just as all Big Pharma companies do, Merck must have calculated that profits from sales would outweigh losses from lawsuits.
In fact, as a study in the Archives of Internal Medicine would later show, Merck, through heavy promotion, sought to create as wide a market as possible for Vioxx. (The study revealed that 73 percent of people who took Vioxx did not need a coxib, that a standard NSAID like aspirin would have been sufficient.) Apparently, selling Vioxx as a niche drug for people who really did suffer G.I. problems from NSAIDs, and who were at low risk for heart disease, did not meet Merck’s profit-and-loss forecast.
Merck initiated several more studies of Vioxx, all primarily intended to uncover further potential markets for the drug. In each case, it avoided delving specifically into possible C.V. complications. Most notable was the APPROVe study, which looked toward the prevention of colon polyps, as well as other studies for possible treatments for colorectal and prostate cancer.
In September 2004, when the APPROVe trial revealed the same twofold increase in C.V. complications as the VIGOR study, Merck recalled Vioxx. Even then, Dr. Alise Reicin, vice president of clinical research at Merck, reiterated that this was a puzzling finding. She said that Merck has so far been unable to identify a mechanism behind the increased risk. The fact is that Merck avoided initiating studies to find one.
To further distance Merck from any responsibility for those who had recently begun taking Vioxx, Kim added, “While the cause of these results is uncertain at this time, they suggest an increased risk of confirmed CV events beginning after 18 months of continuous therapy.”
No, the risk didn’t begin after 18 months. This would be analogous to saying that daily sunbathing for 18 months poses no risk for melanoma if no melanomas are detected during that time, and that the risk doesn’t begin until the melanomas are first discovered. The risk is present from the beginning but only evident at 18 months.
Finally, Merck is asking us to believe that it didn’t suspect from the outset that Vioxx might increase the risk of heart attacks and strokes. It’s telling us that its studies were adequately designed to detect both the incidence and possible underlying mechanisms of cardiovascular risks. It wants us to accept that a nine-month study, abruptly concluded, was insufficient evidence for the withdrawal of Vioxx because it was reasonable to presume that naproxen had a cardio-protective effect.
For me, the sad but inescapable conclusion is that Merck made an informed decision to avoid knowing the full extent of Vioxx’s potential risks for heart attacks and strokes.
And the FDA was either extraordinarily lax or frankly complicit. In April 2002, the federal agency did state that Merck must affix a new label to Vioxx, advising doctors to use caution when prescribing it to patients with heart disease. But it didn’t rule that the drug be withdrawn from the shelves.
Based upon their review of available data about Vioxx, a team of medical scientists from the University of Berne, Switzerland, published this summary in a December 2004 issue of Lancet: “Our findings indicate that Vioxx should have been withdrawn several years earlier. The reasons why manufacturer and drug licensing authorities did not continuously monitor and summarize the accumulating evidence need to be clarified.”
This situation is not likely to change. On at least three occasions, Congress has voted to approve partial FDA funding by pharmaceutical companies. Beginning in 1992 with the passage of PDUFA — the Prescription Drug User Fee Act — pharmaceutical companies have been paying up to $500,000 for each new drug application. Currently, greater than 50 percent of drug reviewers at the FDA are funded by the pharmaceutical industry.
According to the Center for Science in the Public Interest, 10 of the 32 FDA advisory board members who, in 2005, recommended the continued sale of coxibs, had previously consulted for Merck, Pfizer or Novartis. (Pfizer and Novartis have not withdrawn their coxibs, Celebrex and Prexige, respectively, from the market.) To be fair, this isn’t entirely damning, as many top researchers have ties with pharmaceutical companies yet maintain unbiased positions. Dr. FitzGerald, one of Merck’s harshest critics, has received research funding from Merck.
When Merck withdrew Vioxx, the FDA responded: “The risk that an individual patient taking Vioxx will suffer a heart attack or stroke related to the drug is very small.” This is both true and profoundly misleading.
A truly independent agency for the evaluation of new drugs is essential. But the unfortunate truth for the foreseeable future is that we are dependent upon the pharmaceutical industry and its hired security guards — the FDA — to police itself.
We are not helpless. We do have one ace in the hole — the simplest and most difficult of questions. Do I need this medication? Or, as Ray would say, is this the only game in town and do I need to play?
If you have rheumatoid arthritis and can barely dress and feed yourself, a doubled chance of a heart attack on Vioxx might be an acceptable trade-off for increased mobility. A disabling stroke, no matter how unlikely, doesn’t seem like a reasonable risk for a twinge of tennis elbow.
The decision to take any medication is highly personal, a reflection of everything from genetic predispositions to cultural values to the loftiest of metaphysics. It cannot depend exclusively upon statistics. An honest and thorough medical system can provide the information, but the old saw, know thyself, is essential to such choices.
So is know thy playing partner.
And the key to making the right personal decision is that we need transparency of data. We need to get our hands on the deck and look for ourselves. There are plenty of smart and independent folks who could sift through the information and give us an informed opinion. We must demand that study data be made publicly available to those without a vested interest.
The best place to start is with your own family doctor. If you and your physician had adopted Ray’s approach to medication, you would have known in August 2001 that leading cardiologists such as Dr. Topol had major concerns about possible Vioxx C.V. effects. And you would have carefully discussed the labeling change ordered by the FDA in 2002. Unless you are an Internet health letter, medical journal junkie, only your doctor would have received this news in a timely fashion.
However, the problem of post-approval drug side effects will not go away. After 30 years on the market, it is still unclear as to the C.V. effects of the allegedly “safe” NSAIDs such as Aleve. We have to anticipate the unknown, accept certain knowledge limitations, and trust someone to be our advocate in an ever more confusing medical landscape. And we need to balance a well-deserved skepticism with an equal appreciation of what modern medicine has accomplished.
In the big picture, Merck has had an outstanding reputation. It offers a variety of formidable drugs that both improve and save lives. As a niche drug, prescribed to those unresponsive to the older NSAIDs, or to those with unacceptable G.I. complaints or at high risk for ulcers or bleeding, Vioxx would have been a good alternative. If the properly designed studies had been carried out, and we had been given full and prompt access to the data, we could have made our own smart choices. It’s a tragedy that Vioxx led to fatal heart attacks and strokes. And it’s a sad irony that those who were clearly benefiting from the drug no longer find it available to them.
I confess the idea of babies carrying on philosophical investigations never crossed my mind until I met Alison Gopnik, professor of psychology at University of California, Berkeley. Gopnik, a cognitive scientist with cross-training in philosophy and common sense, has spent her career carefully and cleverly teasing out the previously unsuspected complexity of a baby’s thoughts. In her new book, “The Philosophical Baby: What Children’s Minds Tell Us About Truth, Love, and the Meaning of Life,”
Gopnik incisively and compassionately highlights the extraordinary range of mental capabilities of even the youngest child.
What makes Gopnik’s book stand out from the myriad recent books on consciousness is her overarching insight into the sophisticated ways that even infants think and scheme. Citing her work and that of colleagues, Gopnik makes a convincing case that, from a very early age, even before the acquisition of language, we are actively engaged in assessing everything from statistics (probabilities) to right vs. wrong in a moral sphere. Recently I sat down with Gopnick for a conversation about how each of us began our thinking, and how kids might presently be looking at the world.
What inspired you to study the “philosophical baby”?
I’ve know since the first time I read Plato, when I was 11, that I wanted to try to think about some of the great philosophical questions. How do we know about the world? How do we understand other people? What is consciousness? Where does morality come from? But by the time I was 11, I was also the oldest child of six siblings and I had the first of my own three babies when I was 23. So I’ve also always wanted to try to answer some equally deep questions about children themselves. How can they learn so much so quickly? What is it like to be a baby? Why do we love them so much?
Like most parents, I think, my children have been the source of some of my most intense joys and despairs, my deepest moral dilemmas and greatest moral achievements. Childhood is a fundamental part of all human lives, parents or not, since that’s how we all start out. And yet babies and young children are so mysterious and puzzling and even paradoxical. They seem so unlike us, yet they actually are us. Sometimes they seem so brilliant, and then the next minute they do something that seems so dumb.
When you read about children, either in ubiquitous parenting books or in memoirs and autobiographies, all you get is the personal. What should I do to make my baby smarter? What did my parents do to make me who I am? The idea of the book was to take a step back from the personal and immediate and think about babies and young children from this wider scientific and philosophical perspective. Thinking about babies could help us understand philosophy and thinking philosophically could help us understand babies.
Why do you think so little has been written about the philosophy of children — that philosophy, for 2,500 years, has essentially excluded thinking about kids?
There are two reasons. Philosophers used to rely on their armchair intuitions about how minds work. If you look at babies casually, your intuition is likely to be that not much is going on. In the ’70s, new video technologies allowed us to develop experimental techniques for investigating babies’ minds. Since then, philosophers are increasingly paying attention to these scientific results, rather than simply relying upon untested intuitions.
The other reason was that for those 2,500 years, there were people who had a great deal of deep experience of babies and who knew all along how important and interesting babies were. But those people were women and the philosophers were men. An Oxford philosopher once told me, “Well, one has seen children about, of course, but one would never actually talk to them.” Now, partly because women like me have become scientists and philosophers, those two areas of human experience don’t seem so separate.
One of the difficulties in knowing how babies think is that they can’t describe their thought processes. Yet psychologists have devised some very ingenious experiments to show that by age 12 to 15 months, infants with very limited vocabulary are already developing a clear cause-and-effect sense of how the world is put together. Without the benefit of much language, how do you think the brain creates this knowledge?
Alan Turing had one of the greatest scientific insights of the 20th century, when he realized that a physical system that was organized in a particular way could do many of the things that a human mind can do. That idea allowed us to build computers, physical systems that can reason and calculate without language or consciousness. The great idea of cognitive science is that the human brain is a computer — though one profoundly different and vastly more powerful than the ones we have now. Once this idea was out there, it made sense to think that babies’ brains were just as capable of computation as adult brains, even though babies might not be able to report what their brains were doing in a self-conscious reflective way. And that’s just what we’ve discovered. In fact, studying babies can give us new ideas about how to design learning computers.
Presumably, if present in very young infants, this ability must be innate, as if our brains are hard-wired to sort out cause-and-effect even before we acquire language.
Well, developmental psychologists won’t say something is innate unless we’ve found it in newborn babies — which is tough, but remarkably, not at all impossible! So babies might actually somehow develop these causal learning methods in the first few months of life. But they certainly are there very early.
How is this different from the ways in which other animals learn about the world?
Animals are certainly more sophisticated than we used to think. And we shouldn’t lump together animals as a group. Crows and chimps and dogs are all highly intelligent in very different ways. Crows are amazingly sophisticated at understanding how physical objects like wires and twigs work. Living with us seems to have led dogs to evolve to be enormously clever at making people think they are loved. You could think of them as Stepford Wolves. But in a way that’s just the point. Animals seem to home in on very particular kinds of causal relationships that are important to their survival. They also rely heavily on trial and error to learn which actions are effective on the world. But human children learn abstract cause-and-effect relationships just for the fun of it, even when they’re not particularly relevant to survival.
Old-line psychologists such as Piaget thought that children didn’t understand cause-and-effect until they were well into their school years. Why didn’t earlier psychologists notice that young children could easily construct complex theories of causation?
Piaget observed babies tremendously closely and he realized just how philosophically important and interesting they were — though much of the observation was actually done by his wife, Valentine. But even closely observing young children doesn’t really tell you what they can do. For example, we’ve discovered that young children have much better cued memory than spontaneous recall. If you ask a 3-year-old an apparently straightforward question like “How does this machine work?” you’re likely to get a sweet look and either silence or stream of consciousness poetry. But if you ask them, “Does the blue block make it go or does the yellow block make it go?” they will give you the right answer. You have to ask babies and children questions in their language, not ours. It’s taken us 30 years to figure out how to do that, and we’re still learning.
Very young children readily imagine a variety of outcomes to any given situation. For example, 2-year-olds can tell you that if their imaginary teddy bear is drinking imaginary tea and spills it, the imaginary tea will have to be mopped up. Is this ability to imagine the what-ifs of life what most separates human from non-human thought?
I think so, though again animals are smarter than we thought. Still, humans have a special ability to think “counterfactually,” to imagine what might have happened rather than remember what did happen, and animals certainly don’t do that as much as we do. For better or worse, we live in possible worlds as much as actual ones. We are cursed by that characteristically human guilt and regret about what might have been in the past. But that may be the cost for our ability to hope and plan for what might be in the future.
If the ability to imagine cause-and-effect begins before children have well-developed language and reasoning skills, does this tell us that the origins of the kinds of questions we ask are also deeply rooted in our biology?
Well, of course, everything about us is rooted in our brains. But brains aren’t fixed by our genes. Instead they are dramatically plastic, capable of changing to fit all those new environments we encountered when we started our Pleistocene wanderings, and the even more remarkable new environments we create for ourselves. Asking questions is what brains were born to do, at least when we were young children. For young children, quite literally, seeking explanations is as deeply rooted a drive as seeking food or water. What we do as scientists and philosophers is an extension of that childhood drive — the questions keep changing but the drive to ask them is what makes us human.
I remember my mother quoting Dr. Spock as “the authority” on child rearing. Now there are theories to satisfy any parenting position. Some psychologists such as Judith Harris have gone so far as to suggest that parenting has little long-term effect on how children think. Where do you weigh in?
This is an interesting case of the way that scientific importance and everyday interests are at odds. Parents tend to focus on very small differences — like whether my kid will be more likely to get into Harvard than yours — among children who are otherwise living in very similar environments. But, scientifically, we wouldn’t expect to be able to say much about differences at that scale. We can’t predict very much about how my parenting, as opposed to that of my friends, will influence my child as opposed to theirs, which is what all those parents want to know.
What do you think makes one a better parent?
Well, I can tell you what won’t make you a better parent or your child any smarter. The science can tell you that the thousands of pseudo-scientific parenting books out there — not to mention the Baby Einstein DVDs and the flash cards and the brain-boosting toys — won’t do a thing to make your baby smarter. That’s largely because babies are already as smart as they can be; smarter than we are in some ways. In the relationship between early experience and later life, there is not a shred of scientific evidence that any of that makes a difference.
That doesn’t mean, as people like Judith Harris say, that parenting itself doesn’t make a difference. It makes an enormous difference. Even the most self-consciously “bad” parent is already putting a lifetime’s worth of effort and energy and care and devotion into the life of their child, effort and care and love that would be saintly if you devoted it to anyone else. It also isn’t that there’s some innate program that requires just a minimal amount of nurturing to unfold. Specific changes and differences in caregiving make a vast difference. Reading and schooling have made an enormous difference to children. Poverty has an enormous impact on children. Children learn all the contours of daily life from their parents. To conclude that parenting has no effect is like saying that because I can’t tell you specifically whether carbon emissions will cause a hurricane in New Orleans this year, global warming has no effect on the weather.
There’s a more profound philosophical, and even moral point, here. We can’t predict much about how our parenting will influence our children in the long term. Many people may achieve great things as adults, in spite of or even just because of, the fact they were miserable as kids. But we have enormous power over our child’s lives when they are children. We can determine whether our children thrive as children, and whether they remember that thriving childhood as adults. Isn’t that actually more important? Instead of anxiously asking will my caregiving make my son go to Harvard 20 years from now, why not proudly think my caregiving will make my son have just the life that I shape for him, right now, with my particular jokes and quirks and devotion?
Do you think your work has made you a better parent?
Being a developmental psychologist didn’t make me any better at dealing with my own children, no. I muddled through, and, believe me, fretted and worried with the best of them. But I think it did make me even more appreciative of the richness and complexity of children’s minds, and watching them certainly made me a better scientist.
In the ’80s, as I began to wonder how we come to understand others people’s minds, my 2-year-old, Andres, had to cope one night with pineapple with kirsch as dessert. For months afterward, he would thoughtfully remark, apropos of nothing, “Mommy, you know, pineapples — they’re yummy for you but yucky for me.” And that became the germ for a whole line of studies that showed that toddlers are far from being the egocentric solipsists we once thought, and how they, and therefore we, start to understand that other people can want something different than we do.
Children, by being less focused, have a greater general awareness and ability to imagine than us older fossils. Is there a take-away message for how to maximize a child’s free spirit and imagination while, at the same time, forcing her to spend the hours necessary to learn algebra, geometry and the capital of Peru?
The message is that there is a necessary trade-off between two different kinds of intelligence — a trade-off built right into our evolutionary nature. On the one hand, there is our childhood ability to imagine and explore a very wide range of possibilities and to learn new causal maps without caring about their immediate usefulness. On the other, there is our adult ability to put that learning to work to plan and act effectively, swiftly and automatically. Babies and young children are useless on purpose. They are unable to focus, plan and act, so they can wander and dream and play. We grown-up caregivers do the planning and acting for them.
For most of history, education, in the form of apprenticeship, was about turning the discoveries of early childhood into the narrow, focused, automatic competencies of adulthood. But sometime in the 17th century, we discovered that we could reproduce this evolutionary division of labor among adults. We could have professional scientists, for example, who just got to explore and learn about the world without exploiting it for any useful purpose. And we could have institutions like universities, where adults got to do the same thing. Or at least were supposed to; the real function of universities is mostly assortative mating. So we began to try to develop both types of intelligence at once, to have a school system that rewards flexibility and imagination and competence at the same time.
I think we should encourage a kind of cognitive bilingualism in both adults and children. We should have times in our lives or institutions when we can learn and explore and play, and other times in which we can plan and execute and work. An unsung joy of caregiving and child rearing is that it gives you a wonderful opportunity to recapture the imagination and play of childhood at the same time that you’re doing the most important kind of adult work there is.
“The Philosophical Baby” is not exactly a how-to book for parents. But if it were, what can reading it do for parents?
It will do the same thing that reading about the stars does. You gaze up at the stars and they’re awesome. And then you read about astronomy and the next time you gaze at the stars you realize, “My God, they really are awesome.” Parents gaze at their children, when they’re not driving themselves crazy with parenting books, and think, “They’re amazing!” And what I can tell them is, “You don’t know the half of it, they’re even more amazing than you think!”
Continue Reading
Close
When I was finishing my neurology residency, a junior professor in internal medicine asked me if I’d like to create a research project with him. I told him I didn’t have a subject in mind. He replied, “No problem. We’ll find a group of people with a common ailment and run all the lab tests imaginable. Something abnormal is bound to turn up and we can cash in on being the first to discover it.”
I thought of this conversation the other evening when, for what seemed like the hundredth time, I saw Pfizer’s most recent TV commercial for Lyrica, a drug to treat the chronic-pain syndrome, fibromyalgia. I can tolerate Pfizer’s endless ads for Lipitor, the cholesterol-lowering drug, because the ad is doing a public service. High cholesterol is a serious health problem. But watching the kindly middle-age actress interrupt the evening news to tell me that “my fibromyalgia is real” raises serious medical issues and underscores the ruthless drive of Big Pharma.
Since its original description in the late ’70s, experts have held widely divergent views about the cause of fibromyalgia; some even doubt that it is a real condition. Recently, though, with the advent of fMRI scans, researchers have shown that patients with fibromyalgia have different responses to pain than the “normal” population. This discovery holds out “proof” that fibromyalgia is a definitive organic condition requiring specific treatment. That may be good news for people who suffer from the mysterious condition, but it’s great news for the pharmaceutical industry, which can march to the U.S. Food and Drug Administration and seek authorization for a drug to cure the now official disease. Which is exactly what Pfizer did in 2007, earning approval to treat fibromyalgia with Lyrica, already a blockbuster drug.
But hold on. Is that possible? Can an fMRI scan determine the presence or absence of disease? To date, no evidence convincingly shows that fMRI, designed to measure cerebral metabolism, is sufficient to diagnose a specific underlying disease. So what’s going on here?
Let’s begin with a closer look at fibromyalgia itself. Despite strong convictions on all sides, nobody knows whether fibromyalgia is a primary medical condition, part of a larger constellation of other ill-defined conditions, such as chronic fatigue or irritable bowel syndrome, or a label given to a variety of physical complaints that arise out of various mental states, such as anxiety and depression. There haven’t been any reproducible and clear-cut objective findings, such as blood and lab tests, X-rays or anatomical abnormalities on biopsy, to provide a satisfactory understanding of the disease. Even the 1990 American College of Rheumatology diagnostic criteria — widespread muscle pain of more than three months, unassociated with other known illnesses, and the presence of at least 11 tender points over 18 muscle groups — are nothing more than subjective patient descriptions.
By the way, I don’t mean to denigrate patients who experience pain associated with fibromyalgia. My concern is the notion that an fMRI can distinguish between psychological states and so-called “organic” processes that affect how we experience pain. And how patients and physicians respond to the uncertainty of fibromyalgia is often dependent on how they think about “real” vs. “imagined.” Popular mythology has it that if you have physical complaints that arise out of worry and anxiety, the symptoms aren’t as “real” as if they are caused by disease. But this distinction between “real” and “imagined” is both philosophically naive and unfair to patients with psychological conditions.
If you think an inert sugar pill (placebo) is a powerful analgesic, taking it can reduce your level of pain from, say, a dental procedure or wear-and-tear arthritis. Conversely, if you are given the same sugar pill and told it is a new untested drug and might make your pain worse, you might experience more pain (nocebo effect). Your imagined expectation of what the pill might do will affect both your pain perception and what changes will be seen on functional brain imaging. Nowhere in this schema is there any suggestion that changes in pain perception arising out of imagination aren’t real. Placebo-induced relief of pain is clinically identical to pain relief from standard analgesics such as morphine.
Now consider one of the central features of fibromyalgia — an increased number of areas sensitive to ordinary pressure. If you believe you have a condition that makes you more sensitive to painful stimuli, you may well experience more pain than those who believe they aren’t sensitive to painful stimuli. This difference in pain appreciation or description, and the attendant brain changes on fMRI, will not reflect any underlying disease; both will be the reflections of your own self-perception. Even such personality traits such as optimism or pessimism (half-empty vs. half-full), or one’s attitudes toward the medical establishment, can make critical differences.
With this basic principle in mind, let’s look at what fMRI studies are telling us about fibromyalgia. In 2002, Georgetown University researchers compared how 16 women with fibromyalgia and 16 pain-free control subjects responded to both painful and nonpainful stimuli (a small piston generating various amounts of pressure to a thumbnail bed). They found that control subjects required more than twice the amount of pressure to elicit the same degree of pain and fMRI activation as fibromyalgia patients.
The authors concluded: “These results, combined with other work done by our group and others, have convinced us that some pathologic process is making these patients more sensitive. For some reason, still unknown, there’s a neurobiological amplification of their pain signals.”
Perhaps that is true, but amplification of pain signals can also occur simply from imagining an increased pain, as seen with the nocebo effect. So can simple anxiety.
In a subsequent 2007 study, the researchers used the same pain-eliciting techniques but different functional brain scans to look for differences between fibromyalgia patients and controls. This time they found a single region of altered activity between fibromyalgia patients and control subjects — in the right thalamus. The severity of this difference correlated with the degree of fibromyalgia symptoms; the greater the difference, the worse the patient’s symptoms were likely to be. The authors speculate that the findings “are likely the result of neuronal dysfunction.”
But a closer look at this study suggests an alternative interpretation, one more consistent with the notion of how anticipation and expectation can alter brain function.
The researchers found fibromyalgia patients who believe their pain is the result of some external factor, such as a prior injury or exposure to toxic chemicals, experience a higher degree of altered activity on imaging studies. That belief also leads to a higher depression rating on the study questionnaire. The authors comment that attributing clinical symptoms to an external source, even in the absence of clear-cut evidence, is a characteristic feature of chronic pain patients who don’t respond well to treatment.
In short, the described functional imaging findings correlate with patient expectation and belief. What we can’t know is whether the beliefs cause the functional change or are the result of the alleged change. And, more important, there is nothing on the scan to point to whether this activity is or isn’t “normal.” Nevertheless, the authors conclude, “there is really something wrong going on in the brains of the patients with fibromyalgia.”
Of course there is a physiological explanation for the pain of fibromyalgia. Ultimately there is a physiological explanation for all experience, whether it be pain, love or the hallucinations of acute psychosis. The issue isn’t whether a condition is associated with “brain changes” on functional imaging, but whether such changes reflect a specific organic disease as opposed to a psychological state of mind.
And let’s not kid ourselves. Researchers at big pharmaceutical companies are fully aware of the subtleties of how fMRI is performed and what interpretations can be drawn from even questionable studies. They realize that studies on chronic pain are notoriously difficult to interpret and prone to faulty interpretations. They understand overall results can be skewed by underestimating or misassigning the placebo effect. But the stakes are enormous; finding medical literature to support a claim that will dramatically boost sales is like striking gold.
Once a condition has been “authenticated,” it’s only a matter of time before Big Pharma steps in with a treatment. Armed with such “objective” fMRI evidence that fibromyalgia is a bona fide condition, Pfizer undertook a series of clinical studies that showed that some patients with fibromyalgia did experience at least partial relief of symptoms with Lyrica. (On a scale of 1 to 10, the fibromyalgia patients achieved an average reduction in symptoms of 2, whereas the controls given placebo had a 1 point reduction.)
As the result of these studies, in 2007, the FDA approved the use of Lyrica for the treatment of fibromyalgia. (Since the approval in 2007, it has been estimated that worldwide sales of Lyrica have increased 30 percent, to well over $2 billion annually.) Without making specific claims about what fibromyalgia is or how Lyrica works, Pfizer, on its Web site, states that “recent research suggests that changes in the central nervous system may be responsible for the chronic pain that comes with fibromyalgia.” It adds that nerve damage may occur because of an infection or injury.
Suggesting that patients with fibromyalgia might have altered or damaged brain cells is based in part on fMRI studies. From there it’s a short commercial step to suggesting that there could be an underlying infection or injury to fibromyalgia, for which there is no convincing evidence to date.
What isn’t mentioned on the Pfizer’s fibromyalgia Web site is that Lyrica has been approved in Europe for the treatment of generalized anxiety. Lyrica was shown to be effective in providing relief of both emotional symptoms, such as depressive symptoms and panic, as well as physical symptoms, including headaches and muscle aches. Yes, another way of thinking about the benefit of Lyrica is that it helps relieve the muscle aches and pains associated with generalized anxiety and that these may be the same aches and pains as described by patients diagnosed with fibromyalgia. (Without objective lab studies, this distinction is impossible to make.)
Now, perhaps a counterargument could be made that the fMRI changes in fibromyalgia are different than those with generalized anxiety. But to make this argument, we would need to have clear-cut and reproducible findings specific to fibromyalgia, and we should know precisely what such specific regional differences mean, from what the brain is doing to how accurately these changes predict both behavior and what the person is experiencing. So far, we have none of the above.
The fMRI is a wonderful, rapidly evolving technology; much of the research is in its infancy and will undoubtedly change as both the machinery and our understanding of the techniques improve. Meanwhile, the follies of bad and excessive interpretations continue to be both well documented and generally overlooked in the popular press. Of these excesses, I can imagine none with more potential for harm than “objectifying” a clinical syndrome without good peer-reviewed additional data.
The primary tenet of medicine is to do no harm. Everyone involved in the study of controversial conditions such as fibromyalgia — physicians, researchers, pharmaceutical companies and the FDA — has a huge moral obligation to be sure that questionable conclusions aren’t foisted on the public as the final word, particularly without a clear understanding of whether such claims have their own adverse side effects. If beliefs change brain function, false beliefs in the mechanism of a condition can have real and lasting adverse effects.
If a patient believes that there is something “wrong with my brain,” the effects can be disastrous. Anyone who has been told of a possible abnormality on a lab test knows how hard it is to shake off that disturbing knowledge even when repeat studies turn out to be normal. If a single lab test result can generate persistent anxiety despite contrary evidence, imagine the degree of negative expectation generated in those with fibromyalgia when they watch the woman in the Pfizer TV ad claim “my fibromyalgia is real.” If negative expectation (the belief that you are more sensitive to pain than others because of a condition that has altered your pain perception) plays a significant role in the production of fibromyalgia symptoms, Pfizer runs the risk of creating or augmenting the very symptoms it is trying to treat. Talk about a vicious feedback loop!
Before jumping to conclusions about diseases and their causes, we need a more comprehensive and philosophical approach to how we integrate new technologies with basic understanding of human nature. We need to look at how thoughts, beliefs and expectations can generate or affect physical symptoms, and vice versa. And we need to abandon concepts like “real” and “all in your head” once and for all.
Continue Reading
Close
As we await the next Supreme Court justice appointment, Barack Obama critics are rallying around the peculiar notion that empathy should not be a factor in interpreting the law. On May 1, the president said, “I view that quality of empathy, of understanding and identifying with people’s hopes and struggles, as an essential ingredient for arriving at just decisions and outcomes.”
When hosting Bill Bennett’s “Morning in America” radio show last Friday, Republican National Committee Chairman Michael Steele said, “I don’t need some justice up there feeling bad for my opponent because of their life circumstances or their condition and shortchanging me and my opportunity to get fair treatment under the law … I’ll give you empathy. Empathize right on your behind.”
It’s astounding that a trait normally considered admirable — one usually sought out in choosing personal relationships, colleagues and associates — is now seen as synonymous with being emotional and partisan, as though being empathetic makes one less rational and reasonable. It’s understandable, given the deplorable nature of partisan politics, that conservative critics would come up with a unified denouncement of whomever Obama chooses. But why settle on an argument that flies in the very face of modern cognitive science and the understanding of how our brains function?
At the heart of the misunderstanding are erroneous assumptions that stripping empathy from decision-making will necessarily improve the quality of the decision, and that one has the ability to consciously control his or her feelings of empathy.
Anyone familiar with modern psychology is aware of the concept of emotional intelligence — that good decisions combine reason and awareness of one’s feelings. As many recent popular cognitive science books have pointed out, the vast majority of our thoughts originate outside of awareness. They stem from neural networks that silently combine our basic biological predispositions with past experience, both remembered and long-forgotten. Present at the very origin of our thoughts, and integral to the final shape of each of our decisions, are the various inherent biological traits that make each human unique.
For example, someone who’s prone to taking risks will have a different perspective on any risk-reward decision than someone who is inherently timid. These differences don’t begin as conscious choices; our biology guides our thoughts in these varying directions. Part of this difference is as basic as our DNA, such as a gene for dopamine-receptor activity being strongly correlated with risky behavior.
Studies on empathy reveal a similarly strong biological component. Even at a personal experiential level, we suspect that some people are naturally more empathetic than others. How much empathy can be achieved through parenting and proper education remains an open question. But such efforts are the hallmarks of how civilized people can overcome the barbarism of pure self-interest. The converse, trying to avoid feelings of empathy, hardly seems like a noble goal.
Until the recent criticism of Obama’s mention of what he seeks in a Supreme Court justice, I had never heard of or considered how empathy might impair judgment. After all, sound judgment is based upon considering all possible information that is available, rather than discarding observations or feelings that aren’t strictly “reason-based.” Furthermore, having a feeling doesn’t mean that you must act on it — unless you believe we have no element of free will, not even the veto power over biased thoughts.
The idea that we can cleanse our thoughts of allegedly negative influences arising out of empathy is profoundly misguided. Listen to the argument of Richard Epstein, a legal scholar and professor of law at the University of Chicago. “Empathy matters in running business, charities and churches,” he argues. “But judges perform different functions. They interpret laws and resolve disputes. Rather than targeting his favorite groups, Obama should follow the most time-honored image of justice: the blind goddess, Iustitia, carrying the scales of justice.” Only one who subscribes to the scientifically outdated notion that we can step back from our thoughts in order to judge them, and strip them of unconscious and emotion-laden influences, could come up with such a half-baked idea.
But to play devil’s advocate, what if one could eliminate empathy from decision-making? Exactly how would this improve our thinking on complex moral issues? Consider for a moment Harvard neuroscientist Joshua Greene‘s view of a famous moral philosophy dilemma:
“A runaway trolley is hurtling down the tracks toward five people who will be killed if it proceeds on its present course. You can save these five people by diverting the trolley onto a different set of tracks, one that has only one person on it, but if you do this that person will be killed. Is it morally permissible to turn the trolley and thus prevent five deaths at the cost of one? Most people say “Yes.’”
Now consider a second scenario. “Once again, the trolley is headed for five people. You are standing next to a large man on a footbridge spanning the tracks. The only way to save the five people is to push this man off the footbridge and into the path of the trolley. Is that morally permissible? Most people say “No.’”
Why the difference? Aren’t pulling the switch and pushing the man into the path of the trolley morally equal in terms of saving the maximal number of lives?
According to Greene, “our differing responses to these two dilemmas reflect the operations of at least two distinct psychological/neural systems.” One system “tends to think about both of these problems in utilitarian terms: better to save as many lives as possible.” This system depends on the dorsolateral prefrontal cortex, a part of the brain associated with “cognitive control” and reasoning — a region felt to be “more controlled, perhaps more reasoned, and relatively unemotional.”
But on fMRI, a second anatomically different neural system — the superior temporal sulcus, posterior cingulate and medial frontal gyrus — responds quite differently, generating a relatively strong, negative emotional response to pushing the man off the footbridge dilemma but not to pulling the switch.
Though not exactly a scientific term, this difficulty or revulsion in pushing the man off the footbridge is often referred to as the “ick factor,” a reflection that certain behavior is intrinsically disgusting or revolting, irrespective of whether it is reasonable. For most people, shoving a man to his death “feels like murder,” while pulling an impersonal lever constitutes a “rational decision.” Whether or not this cognitive dissonance is strictly reasonable is irrelevant; this is how humans think.
What Greene’s studies (duplicated by others) suggest is that brain systems involved with moral judgments must balance utilitarian concerns with deeply rooted emotional tendencies. Both modes of thinking arise out of unconscious brain mechanisms that jostle for priority outside of conscious control. It isn’t hard to imagine that one’s degree of personal empathy toward any situation will be a major factor in how these two systems eventually arrive at a decision. Indeed, fMRI studies show that feelings of empathy are activated in the same general regions as the emotional system that prevents you from pushing the man off the bridge.
From a strictly utilitarian perspective, pushing the man off the bridge is the correct decision. By empathizing with the man and deciding that pushing him is the wrong choice, you are condemning five people to death to save one. In those rare real-life circumstances where the moral decision gets down to a black-and-white calculation, it might seem relatively easy to determine what’s best for society. But even here, the decision has wide-reaching implications not apparent in this simple calculation. If we consistently push one man off a bridge to save five innocent people, we will have an entirely different culture from one that balks at the notion of pure utilitarianism at the cost of any innocent lives. Imagine a society in which you knew that you could, at any moment, be sacrificed for a “greater good.”
But few complex decisions have an obvious, easily calculated solution. We cannot know with certainty that a war is just, embryos have “souls,” or whether an unconscious patient wishes to be kept alive. In such situations, we must look to our feelings. All good legal opinions arise out of a balance between deeply rooted moral feelings and conscious deliberations.
Not surprisingly, one group has consistently been shown to have a much higher percentage of willingness to push the man off the footbridge — those with injuries to the emotional decision-making brain centers. Italian researchers have shown that patients with “focal ventral medial prefrontal cortex lesions” were more willing than controls (volunteers with no evidence of any brain injury) to judge personal moral violations as acceptable behaviors, yet on impersonal judgments, they were comparable to controls. In short, they lacked the “ick” feeling that prevented the controls from making morally revolting choices.
Such prefrontal cortical injuries, if acquired early in life and before normal social skills develop, have been correlated with a variety of personality traits that are commonly bundled together under the labels of sociopath or psychopath — lying, stealing, violence, and lack of remorse after committing such violations.
Some cognitive scientists suspect this at least partially explains adult sociopathic behavior. The suggestion is that there is a subtle functional deficit in the circuitry for processing emotions key to making moral decisions. Kent Kiehl, a Yale psychologist investigating the biological roots of psychopathy, has demonstrated that criminals without a sense of remorse differed from criminals with a sense of guilt: The remorseless psychopaths had far less activity in those regions that automatically and quickly process moral emotions. Paul Eslinger, Penn State College of Medicine neurology professor, after uncovering similar results in a group of patients clinically diagnosed as sociopaths, suggests, “‘Snakes in suits’ may have specific neural deficits that preclude social emotional responses.”
Years ago, I had dinner with a highly respected California State Supreme Court Chief justice, an old friend of mine nearing the end of his career. After musing on some of his many difficult decisions, he turned to me and said, “Robert, I have always identified with the underdog and felt that society had an obligation to protect those without a voice. Do you think I was wrong?”
His question still haunts me with its humility and self-reflection. After all his years on the bench, he continued to re-evaluate how his feelings for others impacted his opinions. Indeed, it’s this wise approach to recognizing the limits of pure reason that we want in our justices, not folks with the blind and scientifically unjustifiable belief that they can keep emotions out of their decisions, or that empathy is somehow a dirty word. But then you need a heart to appreciate how empathy is the basis of good law.
Continue Reading
Close
At age 90, after 30 years of retirement, Ian Thiermann is back at work for $10 an hour as a supermarket greeter, thanks to being bilked out of his life savings by broker Bernie Madoff, perpetrator of perhaps the biggest investment fraud ever by a single person. It is hard to watch a video clip of Thiermann talking about his shattered life without wincing.
And yet, as Thiermann was gamely trying to accept his diminished financial circumstances by handing out fliers for the weekly specials, Madoff, under house arrest and close scrutiny, was busy mailing $1 million worth of old watches to family and friends.
I suspect we all wonder what, if anything, Madoff feels when directly confronted by those he has utterly destroyed. He cooked the books and perpetually lied to his investors. He pulled off the ongoing deception with an utter insensitivity to others. If shown videos of interviews of his victims, would he wince, laugh or simply shrug dismissively and say, “There’s a sucker born every minute.” For me, a glimpse into Madoff’s brain can shed light on the origins of how we treat each other, and perhaps most important, why we treat each other so poorly.
If there’s any single attribute that separates Madoff from the average Wall Street thief, I’d suggest that it’s his extraordinary ability to read what others think and desire, and especially to know what will give them the greatest satisfaction. (In technical jargon, this ability to read another’s thoughts is referred to as Theory of Mind).
From a neurological perspective, a prime candidate for how we learn how others think is the mirror neuron system. In turn, it’s been proposed that this ability to read the mind of another makes it possible for us to experience empathy toward others. We know what they’re thinking and feeling and this triggers a similar response in us.
Behavioral neurologist V.S Ramachandran has referred to mirror neurons as “empathy neurons” or “Dalai Lama neurons.” He believes this system, by allowing us to understand the intentions and desires of others, is the principal driving force behind “the great leap forward” in human evolution. As a result of such claims, the mirror neuron system has risen to the level of accepted folk psychology. According to U.C. Berkeley psychologist Alison Gopnik, “Mirror neurons have become the ‘left brain/right brain’ of the 21st century.”
But Madoff’s behavior raises serious questions about the relationship between mirror neurons and empathy — and represents a golden opportunity to study the as yet puzzling connection between them.
Over a decade ago, Italian neurophysiologist Giacomo Rizzolatti and his colleagues studied motor control in macaque monkeys by placing electrodes in the region of a monkey’s pre-motor cortex responsible for hand movements. To their surprise, they noticed that these neurons fired both when a monkey reached for an object and when the monkey observed someone else (other monkeys and researchers) reach for an object such as a peanut or bit of banana.
The resulting interpretation has been that you recognize the intentions of others by equating their action with what you would do under the same circumstances. These neurons mirror the activity of others and allow you to see the world “from the other person’s point of view.” Marco Iacoboni, collaborator with Rizzolatti and author of “Mirroring Others,” has written that this system is capable of automatically assigning intention to another.
(Although it’s not possible to directly isolate and detect mirror neurons in humans, functional studies — both fMRI and transcranial magnetic stimulation — strongly suggest that we possess a similar brain system, primarily in the inferior frontal and inferior parietal regions).
To have played his investors as flawlessly as he did for several decades, I’m tempted to say that Madoff knew his investors’ minds better than they did — presumably good evidence for a well-functioning mirror neuron system. But contrary to Ramachandran’s view that mirror neurons are synonymous with “empathy neurons,” Madoff gets a zero in the empathy department. Just watch Madoff on the news, disdainfully and without any outward appearance of contrition, remorse, guilt or embarrassment, push his way through a crowd of angry onlookers and reporters. Contrast this contempt and disregard for his accusers with his savvy, sophisticated understanding of what his neighbors might expect from him, and we get a sense of the disconnect between understanding the thoughts of others and genuinely sharing their feelings.
Consider this letter that Madoff posted in his apartment building:
Dear neighbors,
Please accept my profound apologies for the terrible inconvenience that I have caused over the past weeks. Ruth and I appreciate the support we have received.
Best regards,
Bernard Madoff
If Madoff’s mirror neuron system appears clinically intact, and mirror neurons are key to the development of empathy, what allowed him to muster the callous indifference to ruin so many friends and associates? The obvious candidate would be something awry in the emotional centers and empathy circuitry that allow each of us to feel another’s pain and suffering.
In general, there appear to be two distinctly different, albeit overlapping, types of empathy: intellectual empathy, or knowing what someone is feeling; and affective empathy, or experiencing the same feeling as the other person. For example, a life insurance salesman and his wife can attend a funeral of her co-worker. The salesman might understand the mourners are grieving, and yet the sight of their weeping doesn’t affect him emotionally; instead he might feel a bit giddy that the mourners would be easy marks for some term insurance policies. His wife, on the other hand, might become overwhelmed with real grief.
One of the best-studied examples of this disconnect between understanding the feelings of others and sharing their feelings is the patient “Elliott,” described by neurologist Antonio Damasio in his book “Descartes’ Error.” Following the removal of a benign brain tumor, Elliot underwent a dramatic personality change. Although his imaging studies showed bilateral damage to his prefrontal cortex, he scored above average on standard intelligence tests, including some designed to detect frontal lobe damage. He responded normally to standard tests of personality, and retained his ability to speak and reason about topics such as politics and economics.
What was strikingly different was his affect. Although he was able to intellectually recognize emotional content, he now was unable to feel these emotions. When shown pictures of gory accidents such as a decapitated car accident victim, or a child drowning, Elliot reported having no emotional response at the same time as he remembered previously having had strong emotional responses to similar photos. His ability to intellectually experience empathy was disconnected from any affective response.
Even the neural substrates of affective empathy aren’t neatly organized; they vary according to what emotion is being experienced. If you see a woman in danger and feel fearful for her, your amygdala — a limbic system structure critical to experiencing fear and trembling — will light up on fMRI. If you witness quarterback Joe Thiesmann’s leg being broken on Monday Night Football, the anterior mid-cingulate cortex and the anterior insula — two regions that process pain perception — will go into overdrive.
But do we really need to have prior similar experiences to empathize with others? This is the fundamental argument underlying the theory that the mirror neuron system, by providing the ability to read the thoughts and feelings of others, is essential for empathy.
In a January 2009 study, French neuroscientist Nicolas Danziger wanted to see whether a person could empathize with an unfamiliar emotional state. He studied a group of patients with congenital insensitivity to pain — a rare condition present at birth and related to genetic changes in sensory nerves. Such patients have never felt physical pain sensations and have no idea what pain feels like. Interested in seeing how these patients would respond to seeing others in pain, Danziger showed them photos of a person getting her finger caught in gardening shears and a video clip of Theismann’s leg being broken.
Surprisingly, some of the pain-insensitive patients responded on fMRI similarly to normal controls — their pain perception regions lit up. Others had the anticipated lack of response. The difference between the two groups correlated with the degree of empathy that was elicited on a standard empathy assessment questionnaire. The authors concluded that those patients who responded had the “empathy trait.”
If this study pans out and can be duplicated under a variety of similar circumstances, the inference is profound: Each of us is wired differently for feeling the pain and suffering of others, irrespective of our past personal experience.
So is empathy an inborn trait?
One piece of evidence comes from observations on the Autism Spectrum Disorder. Thought to have a strong genetic predisposition, patients with autism and Asperger’s syndrome commonly are unable to grasp what others are thinking and feeling. Listen to this mother of a toddler with Asperger’s syndrome describe his reactions to his 8-month old brother crying whenever he fell down, bumped his head or pinched a finger. “My son asked me the most puzzling questions such as ‘Why is that baby crying?’ ‘Why is he doing that?’ and, my favorite, ‘Can’t we take that noisy baby back to the store and get a new one?’” If genes play a significant role in the Autistic Spectrum patient’s lack of empathy, it stands to reason that there might be a similar genetic contribution to the experience of empathy in all of us.
Further support comes from studies on antisocial behavior, both in young children and in adult “psychopaths.” (I’m using the unfortunately biased term “psychopath” to denote folks with chronic antisocial behavior who lack remorse for their actions, as opposed to antisocial behavior in which remorse and guilt are present.)
Looking at 3,600 pairs of 7-year-old twins, the British Twins Early Development Study found antisocial behavior in 7-year-olds generally fell into two categories: those with normal degrees of empathy and those described as callous and lacking in empathy. The former group was felt to be primarily environmentally mediated (learned behavior), whereas those lacking in empathy demonstrated that their antisocial behavior (primarily bullying and conduct disorders) strongly ran in families. In a subsequent fMRI study, this non-empathic group was shown to have decreased activation of the amygdala in response to looking at fearful faces. In other words, those who lack proper emotional responses to negative stimuli are more likely to have genetic underpinnings to their disorder.
Perhaps the most compelling predictive data supporting the “bad seed” hypothesis is a 25-year study showing that, as early as the age of 3, there are temperamental and physiological difference between those who show psychopathic tendencies as adults and those who don’t. In the early ’70s, 1,800 3-year-olds were observed and rated on several psychological scales, including their degree of fearfulness and inhibition. Twenty-five years later they were reexamined. Those with the higher psychopathy rating scores were found to be significantly less fearful and inhibited and more glib, charming and manipulative.
The authors concluded that children with a low level of fearfulness may be more likely to develop antisocial personality as adults. I’m always leery about accepting purely questionnaire-based studies at face value, but being able to predict the bad seeds at age 3 is hard to entirely ignore.
Although it’s painfully obvious that we don’t know what makes Madoff tick, it is hard not to speculate. If there is such a thing as empathy deficiency, Madoff would be its poster child. Perhaps this was a trait that he shares with his mother, Sylvia Madoff, who was registered as a broker, but in the 1960s was forced to close shop as part of an agreement with the Securities and Exchange Commission not to further investigate her brokerage. (I know it’s impossible with our present state of knowledge to sort out nature from nurture, but the above studies on empathy certainly suggest the possibility of there being a primary biological contribution.)
Even if true, a genetic predisposition for lack of empathy cannot possibly excuse Madoff’s behavior. We all have genetic predispositions for various personality traits — it is our struggle against baser biologic urges that distinguishes us from the rest of the animal kingdom. Deferring to biology as explanation or excuse for a behavior is to abandon all notions of what it means to be human.
Madoff can’t repay his victims, but we can learn from him. That’s why he should be forced to participate in medical studies as part of his sentence. The best cognitive scientists, philosophers, geneticists and sociologists should be allowed to administer to him whatever non-invasive and ethically appropriate clinical studies they can dream up. See if any pattern emerges that is sufficiently reliable to qualify as predictive. Even if our present knowledge is insufficient to draw conclusions, Madoff would make a great set of data points. Perhaps one day he can give something back to society by teaching us about human empathy, and its limitations.
Continue Reading
Close